ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0431

Senescence and Cell Exhaustion in CD4+ and CD8+ Lymphocytes in Rheumatoid Arthritis Patients in Remission Without Treatment

Rodolfo Jiménez-Soto1, Luis llorente2, Guadalupe Lima1, Luisa Alanis Saenz1, Amairani Gomez Rodriguez1, Hilda Marin Lopez1, Erik Cimé-Aké1 and Juan Jakez-Ocampo1, 1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Meeting: ACR Convergence 2023

Keywords: Aging, Cost-Effectiveness, rheumatoid arthritis, T Cell, T-Lymphocyte

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0423–0459) RA – Treatments Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: T cells are important among the several risk factors and immunological markers implicated in rheumatoid arthritis (RA). The goal of this study was to look for biological markers of cell exhaustion in CD4+ and CD8+ lymphocytes from RA patients in remission who were not receiving medication.

Methods: A cross-sectional, single-center study was carried out in a tertiary care center in Mexico City. We included 18-year-old patients who met the EULAR/ACR 2010 RA classification criteria. Patients were divided into three groups: G1) remission for 5 years without therapy with DMARDs and/or glucocorticoids; G2) remission on treatment, and G3) active patients. Pregnancy, active infection, cancer, and the presence of other autoimmune diseases (except Sjogren’s syndrome) were all exclusion criteria. Relevant clinical and serological parameters were recorded, and a univariate analysis was done with SPSS v29. Flow cytometry with Flow Jo v10 was used to analyze the expression of cell exhaustion markers (CTLA-4, LAG-3, PD-1, PD-L1, and Tim-3).

Results: We included 37 patients, 12 (32.4%) of whom were in remission without treatment (G1) and were paired with G2 (32.4%) and G3 (35.1%). The majority (97.3%) were female, the mean age was 57.5 (±12.9) years, and only 5 (13.5%) were smokers. Methotrexate (MTX) was used in 16, hydroxychloroquine (HCQ) in 7, sulfasalazine (SSZ) and leflunomide in 5 each. The mean ESR was 8.22 mm/hr (2-36), and the mean CRP was 1.24mg/dL (0.05-8.74), with no major differences detected between the three groups. When the use of DMARDs was analyzed by group, it was 0%, 57.9%, and 42.1% respectively (p< 0.001). HCQ use was higher in G3, with 0% vs 28.6% vs 71.4% (p=0.032), while SSZ and MTX were more frequent in G2-3, with 0% vs 20% vs 80% and 0% vs 62.5% vs 31.3%, respectively (p=0.046 and p=0.002). Other drugs showed no significant differences. Rheumatoid factor was positive in all patients, while anti-cyclic citrullinated peptide antibodies were positive in 90%, 71.4%, and 100%, respectively (p=0.161). (Table 1) When comparing numeric values between groups, G3 were younger patients and had higher values of ESR and PCR compared to other groups; with ages 64.5 (52.75-73) vs 64.5 (52.5-69) vs 49 (41.5-59.5) years (p=0.039), mean ESR of 4 (2-5) vs 2 (2-5.75) vs 14 (4.5-19) mm/hr (p=0.034), and mean CPR of 0.24 (0.0875-0.4675) vs 0.27 (0.2-1.43) vs 1.52 (0.5-2.455) mg/dL (p=0.008). Other variables were studied; however, no statistical significance was found. (Table 2)Cell exhaustion markers in CD4+ were higher in G2, except for PD-1, with LAG-3, PD-L1, ratio PD-1/PD-L1, and Tim-3 being significant (p=0.0052), whereas in CD8+, only the expression of PD-L1 was significantly different (p=0.0325) (Image 1). These findings suggest that G2 induces increased cell exhaustion, and treatment may be the primary determining factor. However, the limited sample size may have an impact on the findings.

Conclusion: To the best of our knowledge, this is the first study that assess multiple markers of cell exhaustion in RA patients, with expression perhaps related to remission and/or treatment. Further research with larger sample sizes is required to confirm our findings.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: R. Jiménez-Soto: None; L. llorente: None; G. Lima: None; L. Alanis Saenz: None; A. Gomez Rodriguez: None; H. Marin Lopez: None; E. Cimé-Aké: None; J. Jakez-Ocampo: None.

To cite this abstract in AMA style:

Jiménez-Soto R, llorente L, Lima G, Alanis Saenz L, Gomez Rodriguez A, Marin Lopez H, Cimé-Aké E, Jakez-Ocampo J. Senescence and Cell Exhaustion in CD4+ and CD8+ Lymphocytes in Rheumatoid Arthritis Patients in Remission Without Treatment [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/senescence-and-cell-exhaustion-in-cd4-and-cd8-lymphocytes-in-rheumatoid-arthritis-patients-in-remission-without-treatment/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/senescence-and-cell-exhaustion-in-cd4-and-cd8-lymphocytes-in-rheumatoid-arthritis-patients-in-remission-without-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology